Overview
- New Rhein Healthcare Investors, Andera Partners, and Omega Funds led the round, with Sanofi Capital, Kurma Partners, Avego BioScience Capital, and others participating.
- Lead candidate ALV-100, a GIPR antagonist/GLP-1R agonist fusion, is being advanced into Phase 2 to pursue durable efficacy, improved tolerability, and better body-composition outcomes.
- ALV-200, a highly selective amylin receptor 3 peptide agonist, is in IND-enabling and regulatory filing stages, alongside additional injectable and oral amylin-based programs.
- ALV-100’s mechanism mirrors the GLP-1R agonism/GIPR antagonism strategy seen in Amgen’s MariTide program, which outside reports note is in late-stage testing.
- The company is led by veterans from Novo Nordisk and Eli Lilly, is headquartered in Philadelphia with R&D in Copenhagen, has fewer than 50 employees, and licensed its lead asset from Gmax Pharma.